Macular Edema News and Research

RSS
Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

First Edition: June 3, 2014

First Edition: June 3, 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors